<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03557749</url>
  </required_header>
  <id_info>
    <org_study_id>2017NTLS045</org_study_id>
    <secondary_id>MT2017-12</secondary_id>
    <nct_id>NCT03557749</nct_id>
  </id_info>
  <brief_title>Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies</brief_title>
  <official_title>Monitoring of Immune and Microbial Reconstitution in Hematopoietic Cell Transplantation (HCT) and Novel Immunotherapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol serves as a mechanism to collect, store, and distribute bodily fluid and tissue&#xD;
      samples obtained from Hematopoietic Cell Transplant (HCT) or novel immunotherapy patients and&#xD;
      their donors at the Masonic Cancer Center in order to conduct correlative studies of the&#xD;
      immune system, microbiota, and their interactions. Fluid (including but not limited to,&#xD;
      blood, urine, saliva, cerebrospinal fluid, bronchoalveolar lavage fluid) sample log-in,&#xD;
      processing, relabeling, and storage is performed by the Masonic Cancer Center (MCC)&#xD;
      Translational Therapy Lab (TTL).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2018</start_date>
  <completion_date type="Anticipated">January 2030</completion_date>
  <primary_completion_date type="Anticipated">January 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immune Function after HCT</measure>
    <time_frame>7 Years</time_frame>
    <description>Incidence of neutrophil recovery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune Function after HCT</measure>
    <time_frame>7 Years</time_frame>
    <description>Incidence of lymphocyte and monocyte subset recovery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune Function after HCT</measure>
    <time_frame>7 Years</time_frame>
    <description>Incidence of grade II-IV acute GVHD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune Function after HCT</measure>
    <time_frame>7 Years</time_frame>
    <description>Incidence of CMV reactivation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune Function after Cell Therapy/Immunotherapy</measure>
    <time_frame>7 Years</time_frame>
    <description>Incidence of neutrophil recovery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune Function after Cell Therapy/Immunotherapy</measure>
    <time_frame>7 Years</time_frame>
    <description>Incidence of lymphocyte and monocyte subset recovery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune Function after Cell Therapy/Immunotherapy</measure>
    <time_frame>7 Years</time_frame>
    <description>Incidence of cytokine release syndrome (CRS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlate Immune Parameters</measure>
    <time_frame>7 Years</time_frame>
    <description>Correlate the lymphocyte phenotypes, specifically natural killer cell subsets and lymphocyte response to viral antigen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlate microbiota changes and their interactions with the host with outcomes of HCT</measure>
    <time_frame>7 Years</time_frame>
    <description>Correlate microbiota changes and their interactions with the host with outcomes of HCT</description>
  </primary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Immune and Microbial Reconstitution</condition>
  <condition>Systemic Viral Infection</condition>
  <condition>Acute-graft-versus-host Disease</condition>
  <condition>Chronic Graft-versus-host-disease</condition>
  <condition>Recurrent Malignancy</condition>
  <condition>Cytokine Release Syndrome</condition>
  <condition>Allogenic Related Donors</condition>
  <condition>Cell Therapy/Immunotherapy Patients</condition>
  <arm_group>
    <arm_group_label>Immune and Microbial Reconstitution</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Immune Response Triggered by Severe, Systemic Viral Infection</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Immune Response Triggered by Acute Graft-versus-Host Disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Immune Response Triggered by Chronic Graft-versus-Host Disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Immune Response Triggered by Relapse</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Immune Response Triggered by Cytokine Release Syndrome</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Allogeneic Related Donor Samples</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Cellular Therapy Products</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood Sample</intervention_name>
    <description>60 ml heparinized blood 10 ml serum</description>
    <arm_group_label>Allogeneic Related Donor Samples</arm_group_label>
    <arm_group_label>Immune Response Triggered by Acute Graft-versus-Host Disease</arm_group_label>
    <arm_group_label>Immune Response Triggered by Chronic Graft-versus-Host Disease</arm_group_label>
    <arm_group_label>Immune Response Triggered by Cytokine Release Syndrome</arm_group_label>
    <arm_group_label>Immune Response Triggered by Relapse</arm_group_label>
    <arm_group_label>Immune Response Triggered by Severe, Systemic Viral Infection</arm_group_label>
    <arm_group_label>Immune and Microbial Reconstitution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Stool Sample</intervention_name>
    <description>pea-sized amount</description>
    <arm_group_label>Allogeneic Related Donor Samples</arm_group_label>
    <arm_group_label>Immune Response Triggered by Acute Graft-versus-Host Disease</arm_group_label>
    <arm_group_label>Immune and Microbial Reconstitution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Urine Sample</intervention_name>
    <description>10 ml</description>
    <arm_group_label>Allogeneic Related Donor Samples</arm_group_label>
    <arm_group_label>Immune and Microbial Reconstitution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Bronchoalveolar Lavage (BAL) fluid</intervention_name>
    <description>10 ml</description>
    <arm_group_label>Immune Response Triggered by Severe, Systemic Viral Infection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Gastrointestinal biopsy x 2-4</intervention_name>
    <description>rectosigmoid site preferred</description>
    <arm_group_label>Immune Response Triggered by Acute Graft-versus-Host Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Skin biopsy</intervention_name>
    <description>2-4 mm punch</description>
    <arm_group_label>Immune Response Triggered by Acute Graft-versus-Host Disease</arm_group_label>
    <arm_group_label>Immune Response Triggered by Chronic Graft-versus-Host Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Skin, mouth, and/or ocular swab</intervention_name>
    <description>Involved skin, mouth, and/or ocular swab for microbiota studies</description>
    <arm_group_label>Immune Response Triggered by Chronic Graft-versus-Host Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Apheresis Product</intervention_name>
    <description>Up to 10 ml of apheresis product</description>
    <arm_group_label>Cellular Therapy Products</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Final cellular product</intervention_name>
    <description>A second washing from the infusion bag after product and initial bag wash has infused, or up to 10 ml of final cellular product</description>
    <arm_group_label>Cellular Therapy Products</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients receiving care in the University of Minnesota Blood and Marrow Transplant&#xD;
        Program&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients planning to undergo HCT or other cellular therapy/immunotherapy&#xD;
&#xD;
          -  Allogeneic related donors&#xD;
&#xD;
          -  Aged 0-80&#xD;
&#xD;
          -  Willing and able to sign voluntary written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients whose medical record indicates that they have opted out of research&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Timothy Krepsky, RN</last_name>
    <phone>612-273-2800</phone>
    <email>tkrepsk1@fairview.rog</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shernan Holtan, MD</last_name>
    <phone>612-301-1095</phone>
    <email>sgholtan@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Minnesota Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shernan Holtan, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>June 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Cytokine Release Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

